Biphenotypic sinonasal sarcoma (SNS) is a newly described tumor of the nasal and paranasal areas. Here we report a recurrent chromosomal translocation in SNS, t(2;4)(q35;q31.1), resulting in a PAX3-MAML3 fusion protein that is a potent transcriptional activator of PAX3 response elements. The SNS phenotype is characterized by aberrant expression of genes involved in neuroectodermal and myogenic differentiation, closely simulating the developmental roles of PAX3.
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Biphenotypic sinonasal sarcoma (SNS) is a newly described tumor of the nasal and paranasal areas. Here we report a recurrent chromosomal translocation in SNS, t(2;4)(q35;q31.1), resulting in a PAX3-MAML3 fusion protein that is a potent transcriptional activator of PAX3 response elements. The SNS phenotype is characterized by aberrant expression of genes involved in neuroectodermal and myogenic differentiation, closely simulating the developmental roles of PAX3.
Biphenotypic sinonasal sarcoma or low-grade sinonasal sarcoma with neural and myogenic features (SNS) is a recently described tumor that preferentially occurs in the sinonasal area of middle-aged individuals, more often in females 1 . Clinically, SNS is an infiltrative tumor that often recurs locally 1 . We performed cytogenetic analysis of two SNS tumors and identified a previously unreported chromosomal translocation, t(2;4)(q35;q31.1) ( Fig. 1 and Supplementary Fig. 1 ). Transcriptome analysis of one of these cases identified a fusion transcript in which exons 1-7 of PAX3 were fused to exons 2-5 of MAML3 (Fig. 1a) . FISH and RT-PCR studies confirmed rearrangement of the PAX3 locus in 24 of 25 SNS tumors (96%) and identified the PAX3-MAML3 fusion gene in 19 of these tumors (79%) (Fig. 1c,   Supplementary Fig. 1 and Supplementary Table 1) . Five of the remaining SNS tumors exhibited rearrangement of the PAX3 locus without MAML3 involvement, and a single tumor showed rearrangement of the MAML3 locus without PAX3 involvement. These tumors were screened for possible alternate fusion genes, but none were found (Online Methods). No reciprocal MAML3-PAX3 transcript was identified. We did not detect the PAX3-MAML3 fusion in 118 other tumors, including rhabdomyosarcomas, melanomas, and benign and malignant nerve sheath tumors or in 18 normal tissues (including 13 normal sinonasal tissues) (Supplementary Table 2 ).
The fusion sequence predicted a PAX3-MAML3 chimeric protein in SNS tumors consisting of the highly conserved paired-box DNAbinding domain and the paired-type homeodomain of PAX3 fused to the transactivation domain of MAML3 (Fig. 1b) . We hypothesized that the fusion protein would be a potent transactivator of PAX3 response elements. To test this hypothesis, we generated a PAX3-MAML3 cDNA sequence from SNS tumor mRNA and subcloned it into a mammalian expression vector encoding a Flag epitope tag. The resulting 150-kDa Flag-PAX3-MAML3 fusion protein localized to cell nuclei and bound PAX3-binding sites in vitro ( Supplementary  Fig. 2 ). PAX3-MAML3 consistently increased PAX3-driven reporter activity by 50-fold or more relative to empty vector, whereas wild-type PAX3 increased the activity of the reporter by approximately 9-fold (Fig. 1d) . The PAX3-MAML3 protein had transactivation potential on par with that of PAX3-FOXO1, the fusion protein found in most alveolar rhabdomyosarcoma (ARMS) tumors 2 . 
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During development, PAX3 has important roles in the differentiation and migration of neural crest cells and other cells of ectodermal and mesodermal lineage 3, 4 . Specifically, PAX3 functions at a nodal point in the melanocytic, neuronal and skeletal muscle differentiation programs, promoting lineage commitment and blocking terminal differentiation 3, [5] [6] [7] . PAX3 germline mutations are implicated in several human disorders (Waardenburg syndrome and craniofacialdeafness-hand syndrome), and Pax3 mutations are involved in the Splotch phenotype in mice [8] [9] [10] [11] . To better understand the unusual phenotype of SNS and its possible relationship to the developmental roles of PAX3, we performed gene expression profiling and pathway enrichment analysis on 8 SNS tumors and 33 other tumors. Hierarchical clustering by gene expression profile separated SNS from all other tumors (Fig. 2) and showed altered expression of several genes and signaling networks involved in neural crest, skeletal system and general embryonic development ( Supplementary Figs. 3 and 4, and Supplementary Tables 1 and 3) , including the neurogenic genes NTRK3, ALX1, ALX3, ALX4, DBX1, GREM1 and NEUROG2, the myogenic genes MYOCD and MYOD1, and general developmental genes such as BMP5, FGFR2, POU3F3 and POU4F1, among others. Quantitative PCR (qPCR) analysis and immunohistochemistry confirmed overexpression of several of these genes and their corresponding proteins, identifying high levels of NTRK3, a receptor tyrosine kinase that has important roles in neuronal development and oncogenesis 12, 13 , and absent expression of MLANA, a protein involved in melanosome biogenesis and a downstream effector of the PAX3-regulated transcription factor MITF 14 , which was also not expressed in SNS. These studies also showed expression of smooth muscle actin (SMA) and muscle-specific actin (MSA), weak and sporadic expression of desmin and MYOD1, and consistent negativity for myogenin expression ( Supplementary Fig. 5 and Supplementary  Table 1 ). Interestingly, whereas most SNS tumors expressed high levels of MYOD1 mRNA 15 , the corresponding protein for this myogenic transcription factor was detected in only a subset of cases ( Supplementary Fig. 4 and Supplementary Tables 1 and 3 ). This intriguing finding might be explained by post-transcriptional events or the sensitivity of the immunohistochemical analysis for low expression levels of this protein. Taken together, these observations suggest that the SNS phenotype simulates the developmental roles of PAX3 and that the differentiation of this tumor might be modulated by PAX3-MAML3.
MAML3 is a member of the mastermind-like (MAML) family of transcriptional coactivators for the Notch signaling pathway, which is conserved in metazoans and involved in a variety of pivotal cellular processes, including cell proliferation, differentiation and death 16, 17 . A MAML2 fusion gene occurs in most mucoepidermoid carcinomas, the most common malignant salivary gland tumor 18 . In this tumor, exon 1 of the CREB-binding transcriptional coactivator CRTC1 is fused in frame with MAML2 exons 2-5. The encoded CRTC1-MAML2 oncoprotein retains the CREB-binding site of CRTC1 and the transactivation domain and acidic domains of MAML2. Interestingly, CRTC1-MAML2 is able to induce Notch signaling, despite the deletion of the Notch/CSL-binding domain from the MAML2 protein 17 . However, recent studies indicate that the oncogenic effects of CRTC1-MAML2 also involve the cyclic AMP (cAMP)-CREB and AREG-EGFR signaling pathways 19 . In contrast to the findings in mucoepidermoid carcinoma, we did not observe significant changes in the expression of several Notch target genes in SNS tumors (HES1: expression ratio compared to non-SNS tumors of 0.71, P = 0.15; HES7: expression ratio of 0.91, P = 0.81; HEY1: expression ratio Fig. 2d) . Similar results were seen with another Notch reporter, 4×CSL-Luc (data not shown). At this point, it is unclear how the transactivation domain of MAML3 modulates the oncogenic function of PAX3-MAML3, but we did not observe major effects on Notch signaling. Future studies are needed to address this question.
Because nearly all SNS tumors examined showed either the PAX3-MAML3 fusion or PAX3 locus rearrangement, alterations to PAX3 activity might be crucial for the genesis and propagation of SNS tumors. Further, considering the overall structural similarity between the PAX3-MAML3 and PAX3-FOXO1 fusion genes, the study of SNS might increase understanding of ARMS etiology and PAX3-induced oncogenesis. Indeed, comparing the transcriptional profiles of SNS and ARMS tumors, we found several common denominators but also some key differences (Supplementary Table 4) . For example, expression of MET, GREM1, DAPK1 and TCF7L2 was similar in these two tumor types. In contrast, some direct targets of PAX3-FOXO1 or genes that are often highly expressed in ARMS (including FGFR4, MYCN and ALK) were downregulated in SNS. Likewise, ARMS (but not SNS) tumors expressed high levels of several skeletal myogenesis-related genes (for example, MYOG and DES), FGF8, DCX, BVES and CNR1, among others. In contrast, when compared to ARMS tumors, SNS tumors had higher levels of expression of several neurogenic and cytokine-related genes, metalloproteinase genes, PIK3C2G (encoding a poorly understood member of the phosphoinositide 3-kinase (PI3K) family) and MYOCD (encoding myocardin). The functional characteristics of the PAX3 fusion partners-MAML3 and FOXO1-likely contribute to these differences, but intrinsic characteristics of the cell of origin cannot be disregarded.
Two decades ago, Maulbecker and Gruss suggested that "spindle cell sarcomas, particularly those that occur early in the development, should be tested for elevated PAX gene expression" (ref. 4) . Despite the fact that SNS is only occasionally seen in younger individuals, our findings nicely fulfill that insightful prediction. Interestingly, another study reported a malignant peripheral nerve sheath tumor (MPNST) histologically identical to SNS arising in the skull base that harbored a similar chromosomal translocation, t(2;4)(q35;q31), and this tumor very likely represents the same entity as SNS 20 .
In summary, we show here that PAX3-MAML3 is a characteristic fusion gene in SNS that encodes a potent transactivator of PAX3 response elements. SNS tumors aberrantly express genes involved in neuroectodermal and myogenic differentiation, closely simulating the developmental roles of PAX3. Our findings may lead to a better recognition of this sarcoma among other spindle cell sarcomas and may further contribute to understanding of other cancers, including ARMS.
MeTHodS
Methods and any associated references are available in the online version of the paper. 
COMPETInG FInAnCIAL InTERESTSoNLINe MeTHodS
Subjects and samples. A frozen tumor sample was obtained from a single specimen characterized at the cytogenetic level (case 1). Formalin-fixed, paraffin-embedded tumor blocks and histological sections of SNS biopsied or resected between 1956 and 2013 were retrieved for 25 tumors, including a second sample that was also characterized at the cytogenetic level (Supplementary Table 1 ). All SNS cases were originally diagnosed as fibrosarcoma, MPNST and synovial sarcoma. Tumors were retrospectively identified at the Mayo Clinic Tissue Registry and in the consultation files of the authors (A.M.O. and J.E.L.). Formalin-fixed, paraffin-embedded material from 145 non-related tumors and normal tissues was also retrieved (Supplementary Table 2 ). The Mayo Clinic Institutional Review Board approved this study.
Transcriptome sequencing and data analyses. Total RNA was extracted from the frozen material for a primary SNS positive for the t(2;4) translocation (case 1) using a the RNeasy mini kit (Qiagen). RNA concentration was measured using a Qubit 2.0 Fluorometer (Life Technologies). We subjected 1 µg of total RNA to TruSeq RNA sample library preparation using the kit from Illumina. Pairedend 50-base transcriptome sequencing was performed using a HiSeq 2000 sequencer (Illumina) at the Mayo Clinic Medical Genome Facility. FASTQ read files for the sample were used for sequencing data analysis. Briefly, reads were mapped to the human genome reference Build 37 and exon junctions using Burrows-Wheeler Aligner (BWA) 21 . The exon junction database was constructed using the gene definition file downloaded from the UCSC Golden Path database. A junction usually contained 49 bases from the end of one exon and 49 bases from the beginning of the next exon. If the next exon was shorter than 49 bases, the exon after it was used. An exhaustive combination of all exon junctions in a gene in a single direction (from the beginning of the transcript) was constructed. Potential fusion transcripts were detected using the SnowShoes-FTD algorithm developed for paired-end mRNA sequencing data 22 . A total of 412 million 50-base reads were generated from the index case (case 1; Supplementary Table 1), 325 million reads (89.9%) of which were mapped to the genome and 74.5 million reads (18.1%) of which were mapped to exon junctions. Of the mapped reads, 350.5 million mapped to known genes curated by the UCSC Golden Path genomic database. To estimate the percentage of genes that were 'expressed' , gene counts were log 2 transformed (log 2 (gene count + 1)) to avoid log transformation of zero. Similar to the bimodal distributions observed with the cDNA microarray data, the histogram of log 2 -transformed gene counts for this RNA sequencing data also displayed a bimodal distribution, with the distribution around the second mode (corresponding to larger expression values) representing the expressed genes and the distribution around the first mode representing genes whose expression was only detected by chance. We estimated that approximately 68% of the 23,398 genes were expressed. The only two candidate fusion sequences identified were PAX3-MAML3 and GPR128-TFG. The genes involved in the first of these fusion sequences perfectly matched the locations of the chromosomal breakpoints and were further investigated. The fusion transcript GPR128-TFG was only found in the index case, and its biological consequences are unknown.
RT-PCR.
RNA was extracted from a frozen tumor specimen and from formalin-fixed, paraffin-embedded sections for 25 SNS tumors and 136 additional controls (118 tumors and 18 normal tissues) using the High Pure FFPE RNA Micro kit (Roche) or TRIzol Reagent (Life Technologies) after deparaffinization. RNA concentration was determined by Qubit 2.0 Fluorometer (Life Technologies). RNA extracted from tumor and control samples was converted into cDNA with random hexamers using the Transcriptor First-Strand cDNA Synthesis kit (Roche). The GAPDH or PGK1 housekeeping gene was amplified for cDNA quality control. PCR was carried out using Platinum Taq DNA polymerase (Life Technologies) with the following conditions: 94 °C for 2 min; 40 cycles of 94 °C for 30 s, 62 °C for 30 s and 72 °C for 30 s; and 72 °C for 7 min. The PCR primers used for validation and screening for the PAX3-MAML3 fusion are described in Supplementary Table 5 . The PCR primers used for detection of the possible reciprocal fusion gene MAML3-PAX3 and possible alternate fusion genes PAX3-FOXO1, PAX3-MAML1, PAX3-MAML2, PAX3-NCOA1, PAX3-NCOA2 and PAX7-MAML3 are also described in Supplementary Table 5 . PCR products were separated on 3.0% agarose gels, extracted with the QIAquick Gel Extraction kit (Qiagen) and sequenced with a 3730xl DNA Analyzer (Applied Biosystems). Sequences for the PCR products were analyzed using the BLAST program from NCBI.
FISH analysis. BAC clones were purchased from the Children's Hospital Oakland Research Institute (CHORI). BAC clones flanking the two sides of the PAX3 locus included RP11-1033L11, RP11-92G23, RP11-774C7 and RP11-71J24 (centromeric-side probe size = 493 kb) and RP11-1012L13, RP11-157M20, RP11-884B7 and RP11-81I8 (telomeric-side probe size = 489 kb). BAC clones flanking the two sides of the MAML3 locus included RP11-121K15, RP11-53D6 and RP11-946J16 (centromeric-side probe size = 489 kb) and RP11-625H13, RP11-876B4, RP11-542P2 and RP11-5K16 (telomeric-side probe size = 533 kb). BAC clones flanking the two sides of the MAML1 locus included CTD-3243D15, CTD-2335L20, RP11-1058J18 and RP11-983G15 (centromeric-side probe size = 291 kb) and RP11-1148N14, CTD-3221P10, RP11-465D22, RP11-669B15 and RP11-282I19 (telomeric-side probe size = 616 kb). BAC clones flanking the two sides of the MAML2 locus included CTD-544I7, CTD-2252L1, RP11-1123F20, RP11-936C10 and RP11-7D4 (centromeric-side probe size = 623 kb) and RP11-1056O10, CTD-2325K3 and RP11-8N17 (telomeric-side probe size = 372 kb). BAC clones flanking the two sides of the PAX7 locus included CTD-2342P14, RP11-14K12 and RP11-632C1 (telomeric-side probe size = 411 kb) and RP11-998A17, RP4-540O3 and RP11-22M1 (centromeric-side probe size = 429 kb). For FOXO1, we used a commercially available FISH break-apart probe (Abbott Molecular). Preparation and validation of direct-labeled FISH probes and interphase molecular cytogenetic studies were performed using a previously described FISH protocol 23 on 4-µm formalin-fixed, paraffin-embedded sections from 25 cases of SNS and 28 controls. Probe mixtures were custom designed to allow for three probe strategies to be employed: a PAX3 break-apart probe strategy, a MAML3 break-apart probe strategy and a PAX3-MAML3 singlefusion (bring-together) probe strategy using a probe telomeric to the PAX3 locus and a probe centromeric to the MAML3 locus. Greater than 10% tumor nuclei separation was needed to identify a signal pattern indicative of locus rearrangement by FISH.
Cloning of PAX3-MAML3 cDNA. RNA from SNS case 1 was reverse transcribed to cDNA using SuperScript III (Life Technologies). Primers were designed to amplify the predicted PAX3-MAML3 fusion gene and incorporate a Flag epitope tag on the N terminus of the encoded protein, as well as to include BamHI and NotI restriction enzyme sites for cloning. Primer sequences are described in Supplementary Table 5 . The resulting cDNA was subcloned into pcDNA3 and fully sequenced to confirm the fidelity of the RT-PCR and cloning processes.
Immunoblotting and immunofluorescence. Mycoplasma-free human embryonic kidney (HEK) 293T cells (American Type Culture Collection) were transiently transfected with pcDNA3-Flag-PAX3-MAML3 or pcDNA-HA-PAX3 using Lipofectamine (Life Technologies). Cell lysates were prepared after 48 h, resolved by SDS-PAGE and transferred to Immobilon-P membranes (EMD Millipore). Membranes were blotted with antibody to PAX3 (Life Technologies, rabbit polyclonal, 38-1801; 1:1,000 dilution). For immunofluorescence assays, mycoplasma-free mouse mesenchymal C2C12 cells were plated on coverslips and transfected with pcDNA3 or pcDNA3-Flag-PAX3-MAML3. After 48 h, cells were fixed with 4% paraformaldehyde, permeabilized and sequentially incubated with antibody to Flag (Sigma-Aldrich, mouse monoclonal, F1804; 1:100 dilution) and Alexa Fluor 488-conjugated
